Sutro Biopharma Free Cash Flow (FCF) History (STRO)

Sutro Biopharma reported $11.1M in free cash flow for fiscal 2018, an increase of $51.5M from the previous fiscal year, with a free cash flow margin of 28.96%.

View full Sutro Biopharma company overview

Sutro Biopharma free cash flow by year

Sutro Biopharma annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20182018-12-31$11.1M$51.5M+28.96%
20172017-12-31−$40.4M−$22.8M−78.06%
20162016-12-31−$17.5M−29.38%

Sutro Biopharma free cash flow growth trends

Sutro Biopharma's latest reported quarter, Q1 2020, generated −$19.5M in free cash flow, a decrease of $12.8M year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Sutro Biopharma filings at SEC.gov ↗